Matt O'Brien
Stock Analyst at Piper Sandler
(2.51)
# 1,148
Out of 4,754 analysts
182
Total ratings
46.31%
Success rate
-0.17%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TFX Teleflex | Downgrades: Neutral | $255 → $140 | $135.13 | +3.60% | 5 | Feb 28, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $12 → $13 | $12.27 | +5.95% | 2 | Feb 27, 2025 | |
| BBNX Beta Bionics | Initiates: Overweight | $26 | $20.98 | +23.93% | 1 | Feb 24, 2025 | |
| PODD Insulet | Maintains: Overweight | $285 → $310 | $272.64 | +13.70% | 8 | Feb 21, 2025 | |
| PEN Penumbra | Reiterates: Overweight | $250 → $330 | $285.88 | +15.43% | 13 | Feb 19, 2025 | |
| ATRC AtriCure | Maintains: Overweight | $40 → $50 | $38.96 | +28.34% | 3 | Feb 13, 2025 | |
| STAA STAAR Surgical Company | Maintains: Neutral | $40 → $16 | $16.47 | -2.85% | 7 | Feb 12, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $16 → $20 | $12.35 | +61.94% | 8 | Feb 5, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $95 → $115 | $104.87 | +9.66% | 3 | Feb 3, 2025 | |
| GKOS Glaukos | Reiterates: Overweight | $140 → $180 | $109.15 | +64.91% | 9 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $90 | $69.33 | +29.81% | 9 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $8.73 | +37.46% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6 → $5.5 | $2.51 | +119.12% | 6 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $5 | $2.34 | +113.68% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $100 | $79.25 | +26.18% | 11 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $394.88 | +6.36% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $120.21 | +16.46% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $60.60 | +23.76% | 3 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $85.99 | +4.66% | 10 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $94.30 | -4.56% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $1 | $0.32 | +210.27% | 12 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $12 | $13.03 | -7.90% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 → $55 | $20.78 | +164.68% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $58.33 | +37.15% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $17.57 | +42.29% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $40 | $23.15 | +72.79% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $3.06 | -1.80% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $1.32 | +240.91% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $105.38 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.10 | +265.85% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $91.65 | +18.66% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $7.21 | +152.15% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $34.86 | +129.49% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $3.30 | +263.64% | 1 | Jun 24, 2020 |
Teleflex
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $135.13
Upside: +3.60%
Alphatec Holdings
Feb 27, 2025
Maintains: Overweight
Price Target: $12 → $13
Current: $12.27
Upside: +5.95%
Beta Bionics
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $20.98
Upside: +23.93%
Insulet
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $272.64
Upside: +13.70%
Penumbra
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $285.88
Upside: +15.43%
AtriCure
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $38.96
Upside: +28.34%
STAAR Surgical Company
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $16.47
Upside: -2.85%
CVRx, Inc.
Feb 5, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $12.35
Upside: +61.94%
Boston Scientific
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $104.87
Upside: +9.66%
Glaukos
Jan 27, 2025
Reiterates: Overweight
Price Target: $140 → $180
Current: $109.15
Upside: +64.91%
Dec 11, 2024
Maintains: Overweight
Price Target: $110 → $90
Current: $69.33
Upside: +29.81%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $8.73
Upside: +37.46%
Nov 8, 2024
Reiterates: Neutral
Price Target: $6 → $5.5
Current: $2.51
Upside: +119.12%
Nov 8, 2024
Maintains: Overweight
Price Target: $8 → $5
Current: $2.34
Upside: +113.68%
Nov 6, 2024
Maintains: Overweight
Price Target: $80 → $100
Current: $79.25
Upside: +26.18%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $394.88
Upside: +6.36%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $120.21
Upside: +16.46%
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $60.60
Upside: +23.76%
Aug 26, 2024
Reiterates: Overweight
Price Target: $90
Current: $85.99
Upside: +4.66%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $94.30
Upside: -4.56%
Aug 9, 2024
Reiterates: Neutral
Price Target: $3 → $1
Current: $0.32
Upside: +210.27%
Aug 9, 2024
Reiterates: Overweight
Price Target: $15 → $12
Current: $13.03
Upside: -7.90%
Aug 2, 2024
Reiterates: Overweight
Price Target: $50 → $55
Current: $20.78
Upside: +164.68%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $58.33
Upside: +37.15%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $17.57
Upside: +42.29%
Mar 27, 2024
Reiterates: Overweight
Price Target: $40
Current: $23.15
Upside: +72.79%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $3.06
Upside: -1.80%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.32
Upside: +240.91%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $105.38
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.10
Upside: +265.85%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $91.65
Upside: +18.66%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $7.21
Upside: +152.15%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $34.86
Upside: +129.49%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $3.30
Upside: +263.64%